jonathan javitt, ceo of nrx pharmaceuticals, trying to find better ways to treat covid patients, particularly those severely ill. coming up, we're going to talk about omicron and how it is raising the stakes for some vaccine makers. we're going today into the big money tied to these shots, coming up next. ♪ >> we still have some big challenges ahead of us, but if you think back to the uncertainty all of us around the world faced 20 months ago around what we have a vaccine, would we have therapeutics, what would be the path forward, we have certainly made a lot of progress. >> what the data is telling us basically is three doses of the pfizer biontech vaccine will provide for omicron the same protection like the first two doses provided for the initial strain. taylor: that was of course the ceo's of johnson & johnson and pfizer speaking recently about the progress they have made with vaccines. we are focused on the questions that still remain one year after the u.s. shot was first administered. there was some research released today that showed that pfizer and biontech's vaccine as well as t